Dr Steve Alexander's Outputs (2)

Natural product pharmacology: the British Journal of Pharmacology perspective (2024)
Journal Article
Wang, X., Izzo, A. A., Papapetropoulos, A., Alexander, S. P. H., Cortese‐Krott, M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Panettieri, R. A., Patel, H. H., Schulz, R., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., & Ferdinandy, P. (2024). Natural product pharmacology: the British Journal of Pharmacology perspective. British Journal of Pharmacology, https://doi.org/10.1111/bph.17300

Natural products (NPs) have long been used as a rich source of bioactive compounds for drug development. Recent technological advancements have revitalised natural products research as evidenced by increased publications in this field. In this editor... Read More about Natural product pharmacology: the British Journal of Pharmacology perspective.

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review (2024)
Journal Article
Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese‐Krott, M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A., Patel, H. H., Schulz, R., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., Wang, X., & Ferdinandy, P. (2024). Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. British Journal of Pharmacology, 181(11), 1553-1575. https://doi.org/10.1111/bph.16337

In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or int... Read More about Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review.